Tom Powles, Professor at the University of London, shared a post on X:
“TROPICS4 sacituzimab govitecan vs chemo in pretreated UC Annals of Oncology OS & PFS HRs=0.86.
RR 23 vs 14, but G3+ TRAE 67 vs 35% with G5 TRD. While there is activity the tox & lower RR compared to EV/erda was problematic.
Phase 2 Data on 2 other TROP2/TOPO1 ADCs.”
Shilpa Gupta, Director of Genitourinary Oncology and a Professor of Medicine at Cleveland Clinic, reshared the post on X, adding:
“Congrats Tom Powles, Petros Grivas, Andrea Necchi & entire TROPICS-04 team on getting the data out in Annals of Oncology.
It is crucial to learn from negative trials & important lessons were learned from this.”
